147 related articles for article (PubMed ID: 23630208)
21. 90Y/177Lu-DOTATATE therapy: survival of the fittest?
Brans B; Mottaghy FM; Kessels A
Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1785-7. PubMed ID: 21755369
[No Abstract] [Full Text] [Related]
22. Treatment with
Estorch M
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):69-71. PubMed ID: 28257748
[No Abstract] [Full Text] [Related]
23. Complete Resolution of Neuroendocrine Tumor Soft Tissue Metastases After 177Lu DOTATATE PRRT Induction and Maintenance Therapy.
Makis W; McCann K; Buteau FA; McEwan AJ
Clin Nucl Med; 2015 Aug; 40(8):663-6. PubMed ID: 25546219
[TBL] [Abstract][Full Text] [Related]
24. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
de Jong M; Breeman WA; Valkema R; Bernard BF; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():13S-7S. PubMed ID: 15653647
[TBL] [Abstract][Full Text] [Related]
25. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
[TBL] [Abstract][Full Text] [Related]
26. Complete Remission of Metastatic Neuroendocrine Paragastric Carcinoma After "Neoadjuvant" Peptide Receptor Radionuclide Therapy and Surgery.
Schmidt MC; Uhrhan K; Fischer T; Schmitz S; Markiefka B; Drzezga A; Stippel D
Clin Nucl Med; 2015 Aug; 40(8):667-9. PubMed ID: 26053706
[TBL] [Abstract][Full Text] [Related]
27. Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy.
Acar E; Çapa Kaya G; Durak H
Clin Nucl Med; 2016 Nov; 41(11):866-871. PubMed ID: 27607172
[TBL] [Abstract][Full Text] [Related]
28. Large cell neuroendocrine carcinoma of the lung with atypical evolution and a remarkable response to lutetium Lu 177 dotatate.
Escala Cornejo RA; García-Talavera P; Navarro Martin M; Pérez López B; García Muñoz M; Tamayo Alonso MP; Cruz Hernández JJ
Ann Nucl Med; 2018 Oct; 32(8):568-572. PubMed ID: 30051167
[TBL] [Abstract][Full Text] [Related]
29. Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease.
Thiis-Evensen E; Poole AC; Nguyen HT; Sponheim J
BMC Cancer; 2020 May; 20(1):466. PubMed ID: 32448245
[TBL] [Abstract][Full Text] [Related]
30. Polish experience in Peptide receptor radionuclide therapy.
Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
[TBL] [Abstract][Full Text] [Related]
31. Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
Makis W; McCann K; Riauka TA; McEwan AJ
Clin Nucl Med; 2016 Jan; 41(1):50-2. PubMed ID: 26359569
[TBL] [Abstract][Full Text] [Related]
32. Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2015 May; 40(5):e278-81. PubMed ID: 25783505
[TBL] [Abstract][Full Text] [Related]
33. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Kulkarni HR; Schuchardt C; Baum RP
Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
[TBL] [Abstract][Full Text] [Related]
34. Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
Makis W; McCann K; Riauka TA; McEwan AJ
Clin Nucl Med; 2015 Nov; 40(11):877-9. PubMed ID: 26204206
[TBL] [Abstract][Full Text] [Related]
35. Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up.
Sundlöv A; Sjögreen-Gleisner K; Tennvall J; Dahl L; Svensson J; Åkesson A; Bernhardt P; Lindgren O
Neuroendocrinology; 2021; 111(4):344-353. PubMed ID: 32259830
[TBL] [Abstract][Full Text] [Related]
36. Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event.
Karfis I; Marin G; Machiels G; Hendlisz A; Flamen P
Clin Nucl Med; 2018 Jul; 43(7):e232-e233. PubMed ID: 29762236
[TBL] [Abstract][Full Text] [Related]
37. Additional hepatic
Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
[TBL] [Abstract][Full Text] [Related]
38. In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.
Chan HS; de Blois E; Morgenstern A; Bruchertseifer F; de Jong M; Breeman W; Konijnenberg M
PLoS One; 2017; 12(7):e0181473. PubMed ID: 28732021
[TBL] [Abstract][Full Text] [Related]
39. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
[TBL] [Abstract][Full Text] [Related]
40. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
